Clinical Value of Systemic Immunoinflammatory Index in Predicting Recurrence and Metastasis in Patients with Primary Liver Cancer

Overview

Journal BMC Gastroenterol

Publisher Biomed Central

Specialty Gastroenterology

Date 2025 Mar 14

PMID 40082749

Authors

Yang Deng

Zhili Chen

Qiufeng He

Bei Wu

Ting Su

Chuangjie Mao

Rong Hu

Affiliations

Soon will be listed here.

Abstract

Background: Primary liver cancer is a highly aggressive neoplasm with high incidence and mortality. Due to the high ability to metastasis, the 5-year survival rate of patients with primary liver cancer is poor.

Aim: To investigate the clinical value of systemic immunoinflammatory index (SII) in predicting recurrence and metastasis after interventional therapy in patients with primary liver cancer.

Methods: Total 186 patients with primary liver cancer were included and underwent Transcatheter arterial chemoembolization (TACE), and followed up for 3 years. Then, patients were divided into 110 cases in the recurrent metastasis group and 76 cases in the non-recurrent metastasis group according to presence or absence of recurrence and metastasis. Baseline data, SII and alpha-fetoprotein (AFP) levels were compared. Cox proportional hazards regression analysis was used to analyze factors affecting recurrence and metastasis. ROC curve was used to analyze SII and AFP levels in predicting recurrence and metastasis after interventional therapy in patients. Kaplan-Meier survival curves were used to evaluate the survival of patients.

Results: The SII index and AFP levels in the recurrence and metastasis group were higher than those in the non-recurrence and metastasis group (P < 0.001). Cox proportional hazards regression analysis confirmed tumor size ≥ 5 cm, presence of vascular tumor thrombus, presence of vascular invasion, no tumor capsule, SII index, AFP Levels were closely related to the recurrence and metastasis of patients with primary liver cancer (P < 0.05). ROC curve analysis showed that AUC of SII and AFP predicted recurrence and metastasis after intervention were 0.797 and 0.839, respectively, and the jointed AUC was 0.910. After a 3-years of follow-up, the overall survival rate of the 186 patients was 45.70% (85/186). Kaplan-Meier survival curve analysis showed that patients with high SII levels had shorter survival time than that of patients with low SII levels (P < 0.05).

Conclusion: Preoperative SII was closely associated with early recurrence and metastasis, and combined with AFP may have higher value in predicting recurrence and metastasis after interventional therapy in patients with primary liver cancer.

References

Ma C, Zhang Q, Greten T . MDSCs in liver cancer: A critical tumor-promoting player and a potential therapeutic target. Cell Immunol. 2021; 361:104295. PMC: 7882059. DOI: 10.1016/j.cellimm.2021.104295. View

Li C, He W . Comparison of primary liver cancer mortality estimates from World Health Organization, global burden disease and global cancer observatory. Liver Int. 2022; 42(10):2299-2316. PMC: 9543750. DOI: 10.1111/liv.15357. View

Tu T, Buhler S, Bartenschlager R . Chronic viral hepatitis and its association with liver cancer. Biol Chem. 2017; 398(8):817-837. DOI: 10.1515/hsz-2017-0118. View

Shao Z, Liu X, Peng C, Wang L, Xu D . Combination of transcatheter arterial chemoembolization and portal vein embolization for patients with hepatocellular carcinoma: a review. World J Surg Oncol. 2021; 19(1):293. PMC: 8487116. DOI: 10.1186/s12957-021-02401-4. View

Yu Y, Fu J, Xia P, Chu C . A systematic review and meta-analysis on the efficacy and safety of transcatheter arterial chemoembolization combined with radiofrequency ablation in the treatment of primary liver cancer. Transl Cancer Res. 2022; 11(5):1297-1308. PMC: 9189242. DOI: 10.21037/tcr-22-816. View

Zhao K, Zhou X, Xiao Y, Wang Y, Wen L . Research Progress in Alpha-fetoprotein-induced Immunosuppression of Liver Cancer. Mini Rev Med Chem. 2022; 22(17):2237-2243. DOI: 10.2174/1389557522666220218124816. View

Kars A, Sahin A, Kilic K, Sakat M, Bilen A . Systemic immune inflammation index in differentiated thyroid cancers. Acta Otorhinolaryngol Ital. 2022; 42(2):150-154. PMC: 9132005. DOI: 10.14639/0392-100X-N1665. View

Mehla K, Hollingsworth M . Inflammatory and immune effects on tumor progression. Trends Immunol. 2021; 43(2):93-95. DOI: 10.1016/j.it.2021.11.009. View

Li Z, Qu Y, Yang Y, An W, Li S, Wang B . Prognostic value of the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and systemic immune-inflammation index in patients with laryngeal squamous cell carcinoma. Clin Otolaryngol. 2020; 46(2):395-405. DOI: 10.1111/coa.13689. View

10.

Zhang J, Ji C, Li W, Mao Z, Shi Y, Shi H . Tumor-Educated Neutrophils Activate Mesenchymal Stem Cells to Promote Gastric Cancer Growth and Metastasis. Front Cell Dev Biol. 2020; 8:788. PMC: 7438587. DOI: 10.3389/fcell.2020.00788. View

11.

Ji Y, Wang H . Prognostic prediction of systemic immune-inflammation index for patients with gynecological and breast cancers: a meta-analysis. World J Surg Oncol. 2020; 18(1):197. PMC: 7414550. DOI: 10.1186/s12957-020-01974-w. View

12.

Walzik D, Joisten N, Zacher J, Zimmer P . Transferring clinically established immune inflammation markers into exercise physiology: focus on neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and systemic immune-inflammation index. Eur J Appl Physiol. 2021; 121(7):1803-1814. PMC: 8192383. DOI: 10.1007/s00421-021-04668-7. View

13.

Ge Y, Mu W, Ba Q, Li J, Jiang Y, Xia Q . Hepatocellular carcinoma-derived exosomes in organotropic metastasis, recurrence and early diagnosis application. Cancer Lett. 2020; 477:41-48. DOI: 10.1016/j.canlet.2020.02.003. View

14.

Niu Z, Wang W, Niu X . Recent progress in molecular mechanisms of postoperative recurrence and metastasis of hepatocellular carcinoma. World J Gastroenterol. 2022; 28(46):6433-6477. PMC: 9782839. DOI: 10.3748/wjg.v28.i46.6433. View

15.

Tian B, Yang Y, Yang C, Yan L, Ding Z, Liu H . Systemic immune-inflammation index predicts prognosis of cancer immunotherapy: systemic review and meta-analysis. Immunotherapy. 2022; 14(18):1481-1496. DOI: 10.2217/imt-2022-0133. View

16.

Nost T, Alcala K, Urbarova I, Smith Byrne K, Guida F, Sandanger T . Systemic inflammation markers and cancer incidence in the UK Biobank. Eur J Epidemiol. 2021; 36(8):841-848. PMC: 8416852. DOI: 10.1007/s10654-021-00752-6. View

17.

Qiu Y, Zhang Z, Chen Y . Prognostic Value of Pretreatment Systemic Immune-Inflammation Index in Gastric Cancer: A Meta-Analysis. Front Oncol. 2021; 11:537140. PMC: 7990885. DOI: 10.3389/fonc.2021.537140. View

18.

Jung S, Hao J, Shivakumar M, Nam Y, Kim J, Kim M . Development and validation of a novel strong prognostic index for colon cancer through a robust combination of laboratory features for systemic inflammation: a prognostic immune nutritional index. Br J Cancer. 2022; 126(11):1539-1547. PMC: 9130221. DOI: 10.1038/s41416-022-01767-w. View

19.

Wang Q, Zhu S, Huang X, Liu X, Liu J, Tian G . Prognostic value of systemic immune-inflammation index in patients with urinary system cancers: a meta-analysis. Eur Rev Med Pharmacol Sci. 2021; 25(3):1302-1310. DOI: 10.26355/eurrev_202102_24834. View

20.

Li X, Gu L, Chen Y, Chong Y, Wang X, Guo P . Systemic immune-inflammation index is a promising non-invasive biomarker for predicting the survival of urinary system cancers: a systematic review and meta-analysis. Ann Med. 2021; 53(1):1827-1838. PMC: 8519535. DOI: 10.1080/07853890.2021.1991591. View